REFERENCES
- Committee on Nomenclature and Statistics: Diagnostic and Statistical Manual of Mental Disorders. Ed 2. Washington, D.C., American Psychiatric Association, 1968.
- National Committee on Vital and Health Statistics: International Classification of Diseases. Eighth Revision, Adapted for Use in the United States. Washington, D.C., U.S. Government Printing Office, 1967, vols 1 and 2.
- Wharton, R. N. and Perel, J. M.: Ritalin—an old wine in a new bottle. Sci Proc Amer Psychiat Ass 122: 186–187, 1969
- Phrel, J. M., Black, N., Wharton, R. N. and Malitz, S.: Inhibition of imipramine metabolism by methylphenidate. Fed Proc 28: 418, 1969
- Sulser, I. and Dingell, J. V.: On the role of adrenergic mechanisms in the mode of action of tricyclic antidepressants. In Efron, D. and Kety, S. (Editors): Antidepressant Drugs of Non-MAO Inhibitor Type. Washington, D.C., U.S. Government Printing Office, 1966, pp 1–40.
- Flemembaum, A.: Methylphenidate (Ritalin) and tricyclic antidepressants: Unwarranted side effects? Canad Psychiat Ass J (in press).
- Prange, A. J., Eilson, I. C., Rabon, A. M. and Lipton, M. A.: Enhancement of imipramine antidepressant activity by thyroid hormone. Amer J Psychiat 126: 457–469, 1969
- Parke, D. V.: Factors which affect the metabolism of drugs. In Robson, J. M. and Stacey, R. S. (Editors): Recent Advances in Pharmacology. Ed 4. Boston, Little, Brown and Company, 1968, p 88.
- Chittal, S. M., Abuzzahab, F. S., Sr. and Mannering, G. J.: Inhibition of the in vitro N-demethylation of imipramine and amitriptyline by chlorpromazine and perphenazine. Pharmacologist 11: 251, 1969.
- Edelson, J. and Douglas, J. F.: Benactyzine inhibition of microsomal meprobamate metabolism. Biochem Pharmacol 16: 2050–2052, 1967.
- Lehmann, H. E.: Tranquilizers: Clinical insufficiencies and needs. In Cerletti, A. and Bove, F. J. (Editors): The Present Status of Psychotropic Drugs. New York, Excerpta Medica Foundation, 1969, pp 168–175.
- Abuzzahab, F. S., Sr.: Psychopharmacologic agents in the prevention of psychiatric disorders. Postgrad Med 46: 141–144 (October) 1969.
- Delay, J. and Deniker, P.: Lacunes et besoins en matiere de neuroleptiques. Ibid.11 pp 139–144.
- Crane, G. E. and Gardner, R., Jr.: Psychotropic drugs and dysfunctions of the basal ganglia: A multidisciplinary workshop. Bethesda, Maryland, National Institute of Mental Health, 1969.
- Parkes, J. D., Calver, D. M., Zilkha, K. J. and Knill-Jones, R. P.: Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1: 259–262 (February 7) 1970.
- Schwab, R. S., England, A. C., Poskanzer, D. C. and Young, R. R.: Amantadine in the treatment of Parkinson's disease. JAMA 208: 1168–1170, 1969
- Yaryura-Tobias, J. A., Wolpert, A., Dana, L. and Merlis, S.: Action of L-dopa in drug induced extrapyramidalism. Dis Nerv Syst 31: 60–63, 1970.
- Klein, A. F. and Davis, J. M.: Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, The Williams & Wilkins Company, 1969, p 165.
- Dimascio, A. and Demirgian, E. I.: Antiparkinson drug overuse. Sci Proc Amer Psychiat Ass 123: 52–53, 1970.
- Gershon, S.: Lithium in mania. Clin Pharmacol Ther 11: 168–187, 1970.
- Schou, M.: Lithium in psychiatric therapy and prophylaxis. J Psychiat Res 6: 67–95, 1968.